Cingulate Inc. Company Profile
NASDAQ: CINGHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Cingulate at a glance
Cingulate Inc. (NASDAQ: CING) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Kansas City, KS. Cingulate is led by Dr. Shane J. Schaffer Pharm.D. and employs about 14 people. The company's shares have traded publicly since 2021.
At a market capitalization of $67.5 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001862150, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Cingulate do?
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In addition, the company plans to initiate a clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.
Business description based on the company's public filings.
Company information
- Legal name
- Cingulate Inc.
- Ticker
- NASDAQ: CING
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Shane J. Schaffer Pharm.D.
- Employees
- 14
- Headquarters
- 1901 West 47th Place, Kansas City, KS, United States
- Phone
- 913 942 2300
- Website
- cingulate.com
- IPO year
- 2021
- Market cap
- $67.48M
- SEC CIK
- 0001862150
- Latest annual report
- 10-K · Mar 18, 2026
Companies similar to Cingulate
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| MNOVMedicinova Inc | 1.31 | +3.15% | $67.11M | vs CING |
| MAIAMAIA Biotechnology Inc. | 1.11 | -2.63% | $68.54M | vs CING |
| PLYXPolaryx Therapeutics Inc. | 1.33 | -11.92% | $66.30M | vs CING |
| PMVPPMV Pharmaceuticals Inc. | 0.876 | -33.13% | $66.17M | vs CING |
| COYACoya Therapeutics Inc. | 2.95 | -1.01% | $69.20M | vs CING |
| GOSSGossamer Bio Inc. | 10.72 | -4.54% | $65.57M | vs CING |
| ZYBTZhengye Biotechnology Holding Limited Class A | 1.48 | -2.63% | $70.14M | vs CING |
| FBIOFortress Biotech Inc. | 1.90 | +7.34% | $64.11M | vs CING |